Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Restructuring Costs (2022 - 2025)

Spero Therapeutics' Restructuring Costs history spans 3 years, with the latest figure at $83000.0 for Q2 2025.

  • For Q2 2025, Restructuring Costs changed N/A year-over-year to $83000.0; the TTM value through Dec 2025 reached $258000.0, down 70.58%, while the annual FY2025 figure was $258000.0, 70.58% down from the prior year.
  • Restructuring Costs reached $83000.0 in Q2 2025 per SPRO's latest filing, down from $175000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $877000.0 in Q4 2024 to a low of -$8.6 million in Q4 2022.
  • Average Restructuring Costs over 3 years is -$1.5 million, with a median of $83000.0 recorded in 2025.